Video
Dr. Min Dong discusses next steps with therapeutic toxins for urologic disease
Author(s):
“We are not just changing toxins for the sake of changing toxins; we are changing toxins to satisfy the needs from the clinical community,” says Min Dong, MD.
Video Player is loading.
In this video, Min Dong, MD,summarizes the main points of his talk, “New frontiers in therapeutic toxins for urologic disease,” which was presented at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction 2022 Winter Meeting. Dong is an associate professor of Urology at Harvard Medical School in Cambridge, Massachusetts.
Related Videos
Investigators characterize vibegron prescribing patterns for OAB
Expert outlines advantages of batteryless sacral neuromodulation device
Emmanuel Chartier-Kastler, MD, shares initial data on UroActive System in women with SUI
Smaller size, patient control advantages of neurostimulator for OAB
Batteryless neurostimulator found efficacious at 6-month follow-up
Colin Goudelocke, MD, on 6-month data for batteryless neurostimulator
A physical therapist’s advice for men with post-prostatectomy incontinence
William Furuyama, MD, on community factors’ influence on urinary incontinence
Investigators explore social vulnerability and urinary incontinence
Vanita Gaglani, RPT, discusses books on post-prostatectomy incontinence and prostatitis
Related Content
